BioCryst Pharmaceuticals 8-K Report: Key Updates from January 10, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

1. Filing Type: The report is an 8-K, which is typically used to report unscheduled material events or corporate changes.
2. Company Information:

• Name: BioCryst Pharmaceuticals, Inc.
• CIK (Central Index Key): 0000882796
• Entity Type: Delaware Corporation (DE)
• SEC File Number: 000-23186
• EIN (Employer Identification Number): 62-1413174
• Address: 4505 Emperor Blvd., Suite 200, Durham, NC 27703
• Phone Number: 919-859-1302
• Ticker Symbol: BCRX
• Exchange: NASDAQ

3. Reporting Period:

• Report Date: January 10, 2025
• The report covers a single day, indicating potential specific events or transactions occurring on that date.

4. Units of Measure:

• Currency: USD (U.S. Dollars)
• Shares: The report also references shares, indicating potential share-related activities or disclosures.

5. Context and Schema Reference:

• Schema Reference: The document references a specific XML schema (gnw-20190101.xsd), which likely contains the structure and format for the reported data.

Insights:

• The timing of the 8-K filing on January 10, 2025, suggests that the company may be reporting on significant developments that occurred at the start of the year, which could include financial results, changes in leadership, or new product announcements.
• The company is publicly traded under the ticker BCRX on NASDAQ, indicating a level of scrutiny and obligation to disclose material events to investors.
• The reporting unit includes both monetary and shares, suggesting possible updates on stock performance, equity financing, or stockholder actions.

This report warrants a further detailed review of any specific events or disclosures made in the 8-K filing for potential impacts on the company's operations or stock performance.